Affymetrix Technology Powers First Genomic Tumor Grading Test For Breast Cancer
Affymetrix Inc. (Nasdaq: AFFX) announced that its technology powers the Ipsogen MapQuant Dx? Genomic Grade, the first genomic test designed to provide a more precise measurement of tumor grade than previous techniques. Ipsogen, a leading French molecular diagnostic company, launched the test, which resulted from the Powered by Affymetrix? agreement signed in August 2007.
More... |
All times are GMT -7. The time now is 12:38 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021